Báo cáo thường niên năm 2023 của Cizzle Biotechnology Holdings Plc
Cizzle Biotechnology Holdings Plc engages in developing a blood test for the early detection of various forms of lung cancer. It develops CIZ1B protein gene and its potential as a diagnostic biomarker for detection and management of lung cancer. The company's Ciz1 promotes DNA replication and its organization and control. The company was formerly known as Cizzle Biotechnology Limited and … More changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc was incorporated in 2004 and is headquartered in London, the United Kingdom.
TÊN CÔNG TY / COMPANY Cizzle Biotechnology Holdings Plc
SÀN CHỨNG KHOÁN / STOCK EXCHANGE LSE (England)
MÃ CHỨNG KHOÁN / TICKER CIZ
KỲ BÁO CÁO 2023
NGÀNH / INDUSTRY Biotechnology
LĨNH VỰC / SECTOR Healthcare
LƯU Ý
Xin vui lòng đợi một lát để Báo cáo được tải về, tùy thuộc vào dung lượng của Báo cáo mà thời gian có thể nhanh hoặc chậm.
